Q-omics provides the consensus-scored C9orf24 profile across patient tissues and cancer cell-line models. C9orf24 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, C9orf24 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, C9orf24 RNA expression shows 14,028 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRP, and THYM as cancer lineages where C9orf24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf24 survival associations across molecular data types. C9orf24 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf24 RNA expression–survival associations across cancer types. High C9orf24 expression shows unfavorable associations in ESCA and LGG, but favorable associations in CESC, BRCA, UCEC and ACC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for C9orf24 RNA expression.
This table summarizes C9orf24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf24 shows lower tumor expression in KIRP, THCA, KIRC, LUSC, LUAD and BLCA. The KIRP box plot shows higher C9orf24 RNA expression in normal versus tumor tissue (log2 FC = −2.121, t-test p < 0.001).
This table shows molecular features associated with C9orf24 in patient tissues and cancer cell lines. In patient samples, C9orf24 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
